Addiction treatment and substance use disorder (SUD) M&A activity accelerated sharply through 2025 and into 2026. After a multi-year reset following the late-2010s lab-billing and out-of-network billing scandals — and the COVID-era operating disruption — the sector has emerged with cleaner platforms, more disciplined operators, and renewed buyer appetite.
For owners of MAT clinics, residential treatment programs, intensive outpatient (IOP), partial hospitalization (PHP), and dual-diagnosis programs, 2026 represents a meaningful exit window. This guide covers what sellers should know.
Why Addiction Treatment M&A Is Active in 2026
Three structural forces are driving deal flow:
1. Demand fundamentals.
Opioid use disorder, alcohol use disorder, and stimulant use disorder all remain at elevated levels post-pandemic. Demand for treatment outpaces supply in most markets. Payer coverage has expanded under parity legislation and Medicaid expansion.
2. Cleaner industry post-reset.
The 2017–2020 enforcement wave on lab billing, out-of-network billing, and patient brokering forced bad actors out and clarified compliance norms. Buyers can now underwrite SUD platforms with materially less compliance risk than a decade ago.
3. PE platforms in scale-up mode.
Behavioral health and SUD have become a defined PE thesis with multiple platforms in active build mode. These platforms are aggressive add-on acquirers, creating consistent demand for tuck-in opportunities.
Sub-Sector Valuation Ranges (Q2 2026)
Asset Type
EBITDA Size
Typical Multiple Range
MAT outpatient platform (multi-site)
$5M+
10x–14x
MAT outpatient (single-state, multi-site)
$2M–$5M
8x–11x
MAT outpatient (single-site)
sub-$2M
5x–8x
Residential treatment (premium private pay)
$3M+
9x–13x
Residential treatment (mixed payer)
$2M–$5M
7x–10x
IOP / PHP outpatient programs
$1M–$5M
7x–11x
Detox + residential continuum
$5M+
10x–13x
Dual-diagnosis (SUD + mental health)
$3M+
9x–13x
Multi-state SUD platform
$10M+
12x–15x+
Premiums apply for: diversified payer mix, in-network commercial contracts at favorable rates, demonstrated outcomes data, accreditation (Joint Commission or CARF), strong clinician retention, and clean compliance history.
Payer Mix and Valuation
Payer mix is the single largest valuation variable in SUD M&A. Buyer underwriting differs sharply across payer profiles.
Private Pay
Highest per-episode revenue and margin
Concentration risk if dependent on a single referral channel
Buyers value diversified marketing, repeatable patient acquisition economics, and ethical referral practices
Commercial Insurance (In-Network)
Increasingly the dominant model post-out-of-network reset
Buyers scrutinize contract rates, contract durations, in-network vs. out-of-network mix history, and authorization-to-billing efficiency
In-network platforms with strong rates and durable contracts trade at premium multiples
Commercial Insurance (Out-of-Network)
Significantly discounted by buyers
Compliance risk perceived as elevated
Surprise Billing Act exposure
Rarely supports premium multiples in 2026
Medicaid
Lower margins but more stable demand
Important access platforms; valued differently in mission-aligned PE
Premium multiples for true dual-diagnosis capability
Increasingly the standard of care; non-dual-diagnosis programs face structural pressure
The Most Active Addiction Treatment Buyers in 2026
Strategic Acquirers
Acadia Healthcare (NASDAQ: ACHC) — large strategic acquirer in behavioral health and SUD
Universal Health Services / UHS Behavioral (NYSE: UHS) — selective behavioral health and SUD acquisitions
Behavioral Health Group — MAT platform, active acquirer
Pinnacle Treatment Centers — residential and outpatient SUD
Discovery Behavioral Health — multi-modality behavioral health
Recovery Centers of America (RCA) — residential SUD
Eating Recovery Center / Pathlight Mood & Anxiety Center (where SUD overlaps)
CleanSlate Outpatient Addiction Medicine — MAT-focused
Crossroads Treatment Centers — MAT-focused, active in multiple states
Most Active PE-Backed Platforms
Vistria Group portfolio in behavioral health and SUD
Charlesbank Capital Partners portfolio
Linden Capital Partners — healthcare-only PE active in SUD
Webster Equity Partners portfolio
Bain Capital Double Impact — mission-aligned investment
Cressey & Company — healthcare services PE
Tenex Capital Management — healthcare services
NMS Capital — healthcare services
Multiple independent sponsors focused on behavioral health and SUD
Family offices with healthcare allocations
A well-curated buyer list for an SUD seller typically includes 12–25 firms across these categories — selected based on the seller’s specific service mix, payer profile, and geography.
Diligence Items Unique to SUD M&A
Buyer diligence in addiction treatment is more intensive than in most healthcare services M&A. Expect deep scrutiny of:
Regulatory and Compliance
DEA registration and Schedule II/III/IV/V controlled substance handling
SAMHSA Opioid Treatment Program (OTP) certification (for methadone)
State licensure across all sites
Accreditation (Joint Commission BHC or CARF)
Joint Commission / CARF survey history
Patient brokering / Eddy Act exposure (particularly for residential)
Lab billing compliance — historical and ongoing
Out-of-network billing history
Surprise Billing Act compliance
Patient consent and confidentiality (42 CFR Part 2)
Payer Contract Integrity
Contract rate review by payer
In-network vs. out-of-network history
Authorization-to-billing match analysis
Recoupment and audit history
Clinical and Outcomes
Length-of-stay distribution and clinical justification
Outcomes documentation and measurement methodology
Reflects buyer desire for founder alignment and bridges valuation gaps
Earnout
Common for SUD given outcome and growth uncertainty
Typically 10–25% of total consideration
Tied to revenue, EBITDA, or census metrics over 1–3 years
Sellers should negotiate earnout protection language carefully
Real Estate Carve-Out
For residential platforms, the operating company often sells while the real estate is retained by the seller and leased to the buyer
Produces tax efficiency and ongoing income for the seller
Working Capital Adjustment
Standard mechanism; particular focus on patient A/R aging and authorization-to-payment lag
Common SUD Seller Mistakes
1. Single-buyer conversations.
The active SUD buyer pool is broader than most owners realize. Single-buyer conversations consistently leave value on the table.
2. Underestimating compliance diligence.
Sellers without a clean compliance house in order routinely face material price reductions during diligence. Pre-sale compliance review is essential.
3. Not reconciling lab billing history.
Even programs that have moved away from aggressive lab billing face buyer scrutiny of historical practices. Clear documentation of historical practices and current compliance posture is required.
4. Presenting out-of-network financials as run-rate.
Buyers will not underwrite out-of-network revenue at full credit. Sellers must present in-network forward run-rate clearly.
5. Neglecting outcomes documentation.
Buyers increasingly require evidence of clinical outcomes. Programs that can document outcomes credibly trade at premium multiples.
Preparing an SUD Platform for Sale
The 12–24 months before sale are when SUD platforms most successfully build value.
Operationally:
Migrate out-of-network revenue to in-network where possible
Compliance audit by SUD-specialized healthcare counsel
Patient consent and 42 CFR Part 2 review
Marketing compliance review (LegitScript, etc.)
How Hendon Partners Helps SUD Sellers
Hendon Partners advises owners of MAT, residential, IOP, PHP, and dual-diagnosis platforms through preparation, sale process, and close. Our buyer network includes the strategic acquirers and PE platforms most active in SUD M&A in 2026 — and our process design is calibrated to the specific compliance, payer, and operational dynamics of behavioral health.
For SUD platforms with $1M+ EBITDA, a structured competitive process consistently delivers materially better outcomes than unrepresented sales — both in headline price and in deal structure protection.
Hendon Partners is a specialized healthcare M&A advisory firm with deep expertise in behavioral health and addiction treatment transactions. We advise owners of MAT, residential, IOP, PHP, dual-diagnosis, and detox programs across the United States.
Frequently Asked Questions
What are typical EBITDA multiples for addiction treatment companies in 2026?
+
Multi-state addiction treatment platforms with $5M+ EBITDA trade at 10x–14x. Single-state, multi-site programs with $2M–$5M EBITDA typically clear 8x–11x. Single-site programs with sub-$2M EBITDA generally clear 5x–8x. MAT-focused outpatient platforms can earn premium multiples for clean payer mix and demonstrated growth.
Who buys addiction treatment companies?
+
The most active buyers are PE-backed behavioral health platforms (backed by Vistria, Charlesbank, Linden Capital, Webster Equity, Bain Capital Double Impact, BlackRock Long Term Private Capital, and others), strategic acquirers like Acadia Healthcare and Universal Health Services, regional consolidators, and a growing pool of independent sponsors and family offices.
How do private pay vs. commercial vs. Medicaid affect addiction treatment valuation?
+
Payer mix is one of the largest valuation drivers in SUD M&A. Private pay and well-contracted commercial insurance produce higher margins and higher multiples. Medicaid-heavy programs trade at lower multiples but with greater stability. Mixed-payer programs with diversified commercial and Medicaid mix often achieve the best balance of margin and durability.
Are MAT (Medication-Assisted Treatment) clinics valued differently than residential treatment?
+
Yes. MAT outpatient clinics typically have lower per-patient revenue but higher patient volumes, more recurring revenue, and lower fixed-cost intensity. Residential treatment has higher per-episode revenue, higher fixed costs, and more revenue concentration risk. MAT platforms generally trade at higher multiples for their recurring revenue profile.
What due diligence is unique to addiction treatment M&A?
+
SUD diligence focuses heavily on regulatory compliance (DEA, SAMHSA, state licensure), patient outcomes and length of stay, payer contract integrity, billing compliance (in/out-of-network and laboratory testing exposure), accreditation status (Joint Commission, CARF), and clinician licensure and turnover. Lab billing and out-of-network billing scrutiny are particularly intense given historical industry compliance issues.
